PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
EBIT growth of 49.00% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-9.04%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
48.96%
Net income growth of 48.96% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
53.59%
EPS growth of 53.59% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
51.99%
Diluted EPS growth of 51.99% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
10.21%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.42%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-60.23%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-15675.30%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-5709.37%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-6744.35%
Negative 10Y net income/share CAGR vs. Healthcare median of 18.61%. Seth Klarman might see a fundamental problem if peers maintain growth.
-20067.21%
Negative 5Y CAGR while Healthcare median is 18.20%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-6838.40%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
530.49%
5Y equity/share CAGR of 530.49% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
431.75%
3Y equity/share CAGR of 431.75% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-71.36%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-100.00%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
52.82%
R&D growth of 52.82% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-14.04%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.